Skip to main content

Nanomedicine Based mRNA Vaccine Platform for COVID-19

By 6th August 2021No Comments

The following study was conducted by Scientists from AcumenIST, Brussels, Belgium; Sandra Day O’Connor College of Law, Arizona State University, Phoenix, AZ, USA. Study is published in Nature Communications Journal as detailed below.

Nature Nanotechnology; Volume 16, Pages 362–364 (2021)

COVID-19 May Become Nanomedicine’s Finest Hour Yet

The nanotechnology-enabled mRNA-based vaccine platform recently approved against COVID-19 bears hope for improved vaccine development and trialling capacities in low- and middle-income countries as part of a broader global public health agenda.


Nature Communications



Friedrichs, S., Bowman, D.M. COVID-19 may become nanomedicine’s finest hour yet. Nat. Nanotechnol. 16, 362–364 (2021).